Retinal Vein Occlusion Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Hospital & Clinics is the fastest growing sector, North America is the largest market

The Global Retinal Vein Occlusion (RVO) Treatment Market is projected to experience robust growth, escalating from USD 3.13 billion in 2025 to USD 4.68 billion by 2031, at a compound annual growth rate of 6.93%. This market primarily encompasses pharmacotherapies, notably anti-vascular endothelial growth factor (anti-VEGF) agents and corticosteroid implants, designed to mitigate macular edema and enhance visual acuity in patients afflicted by thrombotic retinal blockages.

The market's expansion is fundamentally propelled by a globally aging population and the increasing prevalence of lifestyle-related risk factors such as hypertension, diabetes mellitus, and cardiovascular disorders, all of which significantly elevate the incidence of retinal vascular events. These systemic health issues compromise retinal vascular integrity, thereby increasing the patient pool susceptible to such events and consequently driving demand for effective pharmacotherapies to manage vision-threatening complications; this is evident in the strong financial performance of leading therapeutics like Eylea HD, which saw significant sales increases following its RVO approval. Additionally, the widespread adoption of advanced anti-VEGF and corticosteroid therapeutics, coupled with a robust pipeline of novel biosimilars, is reshaping market dynamics by addressing the critical need for reduced treatment burden through extended durability, which minimizes the frequency of invasive intravitreal injections and improves long-term compliance, as demonstrated by the rapid uptake of high-strength formulations and the aggressive expansion of innovative retinal therapies such as Vabysmo.

Market Drivers

The escalating prevalence of lifestyle-related comorbidities, particularly diabetes and hypertension, alongside an expanding global geriatric population, stands as a primary catalyst for the retinal vein occlusion treatment market. These systemic health issues significantly compromise retinal vascular integrity, leading to a higher incidence of thrombotic events that necessitate therapeutic intervention. As the patient pool susceptible to these vascular disorders grows, there is a consequential rise in the demand for effective pharmacotherapies to manage vision-threatening complications like macular edema.

This surge in clinical demand is reflected in the financial performance of leading therapeutics; according to Regeneron Pharmaceuticals, October 2025, in the 'Third Quarter 2025 Financial and Operating Results', U.S. net sales of Eylea HD increased 10% to $431 million, driven by higher sales volumes and rising demand following its approval for retinal vein occlusion. Simultaneously, the widespread adoption of advanced anti-VEGF and corticosteroid therapeutics, coupled with a robust pipeline of novel biosimilars, is reshaping market dynamics by addressing the critical need for reduced treatment burden.

Clinicians and patients are increasingly prioritizing next-generation agents that offer extended durability, thereby reducing the frequency of invasive intravitreal injections and improving long-term compliance. This transition toward higher-efficacy treatments is evident in product uptake data; according to Bayer, November 2025, in the 'Third Quarter 2025 Financial Report', the new high-strength formulation of aflibercept has rapidly gained traction, now accounting for more than a quarter of the product’s total sales mix. This competitive shift is further underscored by the broader market momentum, where according to Roche, July 2025, sales of the bispecific antibody Vabysmo surged 18% to CHF 2.1 billion in the first half of the year, highlighting the aggressive expansion of the innovative retinal therapy segment.

Market Challenges

However, the market's growth faces a significant impediment due to the substantial treatment burden inherent in chronic anti-VEGF therapy. While these pharmacotherapies offer functional improvements, the necessity for frequent intravitreal injections creates considerable logistical and psychological strain on patients, leading to injection fatigue, non-compliance, and, ultimately, treatment discontinuation.

This rigorous regimen, often requiring monthly or bimonthly clinical visits, disrupts daily life and incurs significant indirect costs for caregivers, effectively acting as a ceiling on market volume and eroding potential revenue. The severity of this attrition is highlighted by reports that 63% of surveyed specialists experienced patient loss to follow-up in 2025 due to treatment access and burden challenges. Such high rates of drop-out demonstrate how non-compliance, driven by the demanding nature of current delivery methods, directly erodes the addressable market size.

Market Trends

In response, the Global RVO Treatment Market is undergoing a pivotal transformation marked by a shift toward extended-duration anti-VEGF dosing regimens, focusing on developing novel antibody biopolymer conjugates designed to maintain therapeutic intraocular concentrations for much longer periods, thereby enabling biannual dosing without compromising visual gains, as exemplified by positive data from studies on agents like tarcocimab tedromer. Concurrently, the market penetration of cost-effective anti-VEGF biosimilars is fundamentally reshaping the economic landscape of retinal care by dismantling the pricing monopoly of branded biologics. As patents for legacy anti-VEGF agents expire, healthcare systems are aggressively integrating interchangeable biosimilars to manage escalating costs, with strong commercial volume reflecting a robust acceptance of these fiscally sustainable and clinically equivalent alternatives in practice.

Key Market Players

• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Regeneron Pharmaceuticals Inc.
• Taiwan Liposome Company, Ltd.
• Aerie Pharmaceuticals Inc.
• CalciMedica Inc.
• Outlook Therapeutics, Inc.
• Kodiak Sciences Inc.
• Chugai Pharmaceutical Co., Ltd.
• Pfizer Inc.

Report Scope

In this report, the Global Retinal Vein Occlusion Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Retinal Vein Occlusion Treatment Market, by Disease Type:

• Central Retinal Vein Occlusion (CRVO)
• Branch Retinal Vein Occlusion (BRVO)

Retinal Vein Occlusion Treatment Market, by Treatment:

• Anti-vascular Endothelial Growth Factor (Anti-VEGF)
• Corticosteroid Drugs
• Others

Retinal Vein Occlusion Treatment Market, by End-user:

• Hospital & Clinics
• Retail Pharmacy
• Others

Retinal Vein Occlusion Treatment Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Retinal Vein Occlusion Treatment Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.